Live Breaking News & Updates on Pharma

Stay informed with the latest breaking news from Pharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pharma and stay connected to the pulse of your community

Remembering Novartis' Ranjit Shahani: The pharma titan who walked a tightrope for India

Ranjit Shahani will be remembered for his astute leadership and trademark calmness amid chaos. As chief of Novartis in India for nearly two decades, his tenure coincided with unprecedented challenges. Shahani had the tedious task of defending his company from a vexing patent battle while convincing the leadership to look at Indias brighter side. He balanced both with élan.

Ranjit-shahani , Novartis , Shahani , Vasella , Siddharth-shahani , Pharma , Jb-pharma ,

Funding key to pharma target of $130bn: CEOs | Hyderabad News

Innovation, talent, government support, and funding are crucial for Indian pharma to achieve its target of $130 billion by 2030 and $500 billion by 2047. Learn more about the insights from top CEOs in the industry.

Hyderabad , Andhra-pradesh , India , China , Meenakshi-nevatia , Satyanarayana-chava , Piramal-pharma , Satish-reddy , Nandini-piramal , Stefan-stoffel , Pfizer , Hyderabad-news


nikkei.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nikkei.com Daily Mail and Mail on Sunday newspapers.

China , Chinese , Pharma , Turns , Global , Deals , Cure , Capital , Crunch ,

Will India's pharma sector be able to come out of its China dependence?

Indian pharma industry's heavy dependence on imports for active pharmaceutical ingredients (API), key starting materials (KSM) and basic chemicals has been rather alarming, highlighting the need for a resolution.

China , India , Beijing , Chinese , Bloomberg , India-aurobindo-pharma-ltd , Product-linked-incentive , Aurobindo-pharma , Chemical-minister , Compound-annual-growth-rate , Pharma-sector

Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 37 %

In the last two months, there have been phases where the nifty has witnessed a short correction which lasted for anywhere between two to four days. The only difference is that unlike the past when such correction took place, this time when corrections are taking place mid-cap segment also participated. This is indicative of profit booking happening at the broader market level. At this point of time, one cannot rule out volatility which can bring more damage to stock prices in the mid-cap segment. In such times, if one is taking fresh exposure to equity, ensure that there is some level of quality as far as the business and fundamentals are concerned. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.

Google , Market-research , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , End-deal , Economic-times-stories

Zealand Pharma shares surge on liver disease drug trial data, Health News, ET HealthWorld

Pharma: Seeking to challenge obesity treatment market leaders Novo Nordisk and Eli Lilly, Zealand and unlisted Boehringer in June 2023 reported promising phase 2 weight-loss trial results, with the largest and most expensive final stage of testing still to be cleared.

Germany , Zealand-pharma , Eli-lilly , Lilly-mounjaro , Boehringer-ingelheim , Novo-nordisk , Pharma , Epbound , Egovy , Ovo-nordisk , Ounjaro , Ealth-news